scholarly journals TIMP-2 gene rs4789936 polymorphism is associated with increased risk of breast cancer and poor prognosis in Southern Chinese women

Aging ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 19325-19334
Author(s):  
Gaoming Liu ◽  
Jiayou Luo
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Chinese Women ◽  
Southern Chinese ◽  
Increased Risk ◽  
Southern Chinese Women

Genetic imbalances in pT2 breast cancers of southern Chinese women

2001 ◽  
Vol 124 (1) ◽  
pp. 56-61 ◽  
Author(s):  
Lai-Fan Fung ◽  
Nathalie Wong ◽  
Nelson Tang ◽  
Alexander Lau ◽  
Vanesse Wong ◽  
...  
Keyword(s):  
Chinese Women ◽  
Breast Cancers ◽  
Southern Chinese ◽  
Southern Chinese Women

Characteristic findings by phototrichogram in southern Chinese women with Female pattern hair loss

2019 ◽  
Vol 25 (4) ◽  
pp. 447-455 ◽  
Author(s):  
Weihua Mai ◽  
Yixian Sun ◽  
Xingwei Liu ◽  
Daojian Lin ◽  
Dongqing Lu
Keyword(s):  
Hair Loss ◽  
Chinese Women ◽  
Southern Chinese ◽  
Female Pattern Hair Loss ◽  
Southern Chinese Women

scholarly journals FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients

2020 ◽  
Vol 12 ◽  
pp. 175883592091530
Author(s):  
Ning Xie ◽  
Can Tian ◽  
Hui Wu ◽  
Xiaohong Yang ◽  
Liping liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Brain Metastasis ◽  
Poor Prognosis ◽  
Significant Risk ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Genetic Aberrations ◽  
Increased Risk

Background: The survival status of patients with breast cancer and brain metastasis (BCBM) receiving current treatments is poor. Method: We designed a real-world study to investigate using patients’ clinical and genetic aberrations to forecast the prognoses of BCBM patients. We recruited 146 BCBM patients and analyzed their clinical features to evaluate the overall survival (OS). For genetic testing, 30 BCBM and 165 non-brain-metastatic (BM) metastatic breast cancer (MBC) patients from Hunan Cancer Hospital, and 86 BCBM and 1416 non-BM MBC patients from the Geneplus database who received circulating tumor DNA testing, were compared and analyzed. Results: Ki67 >14% and >3 metastatic brain tumors were significant risk factors associated with poor OS, while chemotherapy and brain radiotherapy were beneficial factors for better OS. Compared with non-BM MBC patients, BCBM patients had more fibroblast growth factor receptor ( FGFR) aberrations. The combination of FGFR, TP53 and FLT1 aberrations plus immunohistochemistry HER2-positive were associated with an increased risk of brain metastasis (AUC = 77.13%). FGFR aberration alone was not only a predictive factor (AUC = 67.90%), but also a significant risk factor for poor progression-free survival (Logrank p = 0.029). FGFR1 aberration was more frequent than other FGFR family genes in BCBM patients, and FGFR1 aberration was significantly higher in BCBM patients than non-BM MBC patients. Most FGFR1-amplified MBC patients progressed within 3 months of the late-line (>2 lines) treatment. Conclusion: A group of genetic events, including FGFR, TP53 and FLT1 genetic aberrations, and HER2-positivity, forecasted the occurrence of BM in breast cancers. FGFR genetic aberration alone predicted poor prognosis.

Sign in / Sign up

Export Citation Format

Share Document